Drugs / PF-5190457
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02039349 | Jan 2014 → Oct 2015 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 1 | NCT01522807 | Sep → Nov 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01372163 | Jul 2011 → Apr 2012 | type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01247896 | Dec 2010 → Jun 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02707055 | Jun 2016 → Feb 2020 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-5190457 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3287218 ↗ |
| Known as | PF-05190457 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01247896 ↗ |
| Action | Inhibit | “PF-5190457 is the first inverse agonist of GHS-R1a to progress to clinical development” PMID 33155163 ↗ Nov 2020 |
| Modality | Small molecule | — CHEMBL3287218 ↗ |
| Route | Oral | “Single Escalating Oral Doses of PF-05190457 Under Fasted and Fed Conditions” NCT01247896 ↗ |
| Target | GHSR | “The GHSR blocker PF-5190457 has potential as a novel pharmacotherapy for alcohol use disorder (AUD).” PMID 41474196 ↗ Feb 2026 |